Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease

dc.contributor.authorBarranco Muñoz, Neus
dc.contributor.authorPlá, Virginia
dc.contributor.authorAlcolea, Daniel
dc.contributor.authorSánchez-Domínguez, Irene
dc.contributor.authorFischer-Colbrie, Reiner
dc.contributor.authorFerrer, Isidro
dc.contributor.authorLleó Bisa, Alberto
dc.contributor.authorAguado, Fernando
dc.date.accessioned2021-10-11T11:12:11Z
dc.date.available2021-10-11T11:12:11Z
dc.date.issued2021-09-26
dc.date.updated2021-10-07T07:48:18Z
dc.description.abstractBackground: New fluid biomarkers for Alzheimer's disease (AD) that reveal synaptic and neural network dysfunctions are needed for clinical practice and therapeutic trial design. Dense core vesicle (DCV) cargos are promising cerebrospinal fluid (CSF) indicators of synaptic failure in AD patients. However, their value as biomarkers has not yet been determined. Methods: Immunoassays were performed to analyze the secretory proteins prohormone convertases PC1/3 and PC2, carboxypeptidase E (CPE), secretogranins SgIII and SgII, and Cystatin C in the cerebral cortex (n = 45, provided by Bellvitge University Hospital) and CSF samples (n = 66, provided by The Sant Pau Initiative on Neurodegeneration cohort) from AD patients (n = 56) and age-matched controls (n = 55). Results: In AD tissues, most DCV proteins were aberrantly accumulated in dystrophic neurites and activated astrocytes, whereas PC1/3, PC2 and CPE were also specifically accumulated in hippocampal granulovacuolar degeneration bodies. AD individuals displayed an overall decline of secretory proteins in the CSF. Interestingly, in AD patients, the CSF levels of prohormone convertases strongly correlated inversely with those of neurodegeneration markers and directly with cognitive impairment status. Conclusions: These results demonstrate marked alterations of neuronal-specific prohormone convertases in CSF and cortical tissues of AD patients. The neuronal DCV cargos are biomarker candidates for synaptic dysfunction and neurodegeneration in AD.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2047-9158
dc.identifier.pmid34565482
dc.identifier.urihttps://hdl.handle.net/2445/180534
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s40035-021-00263-0
dc.relation.ispartofTranslational Neurodegeneration, 2021, vol. 10, inum. 1
dc.relation.urihttps://doi.org/10.1186/s40035-021-00263-0
dc.rightscc by (c) Barranco Muñoz, Neus et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMarcadors bioquímics
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.otherBiochemical markers
dc.subject.otherAlzheimer's disease
dc.titleDense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s40035-021-00263-0.pdf
Mida:
3.76 MB
Format:
Adobe Portable Document Format